Phase I studies of ZD1839 in patients with common solid tumors
- 1 February 2003
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 30 (1), 21-29
- https://doi.org/10.1053/sonc.2003.50029
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Tyrosine kinase inhibitors—ZD1839 (Iressa)Current Opinion in Oncology, 2001
- Studies of epidermal growth factor receptor inhibition in breast cancer.Endocrine-Related Cancer, 2001
- EGFR and cancer prognosisEuropean Journal Of Cancer, 2001
- Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancerBioorganic & Medicinal Chemistry Letters, 2001
- Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer TherapyDrugs, 2000
- The Hallmarks of CancerCell, 2000
- EGF receptorThe International Journal of Biochemistry & Cell Biology, 1999
- The Epidermal Growth Factor Receptor and Its Inhibition in Cancer TherapyPharmacology & Therapeutics, 1999
- Synergistic Interaction of the Neu Proto-Oncogene Product and Transforming Growth Factor α in the Mammary Epithelium of Transgenic MiceMolecular and Cellular Biology, 1996
- Epidermal growth factor-related peptides and their receptors in human malignanciesCritical Reviews in Oncology/Hematology, 1995